The Origin Group Limited (TOGL) is the parent organisation and technical service provider to a focused portfolio of UK-based medical technology, research, and innovation companies.
News · Origin · 4 December 2025
Today marks a major milestone for Origin Sciences with the publication of our latest research in Nature Communications: “Hologenomic analysis of rectal mucus sampling for detection of adenomatous polyps and colorectal cancer.” Continue reading…
Origin Sciences Publishes Landmark OriCol™ Study in Nature Communications (News · Origin · 4 December 2025)
The Times Highlights OriCol™ as a Breakthrough in Bowel Cancer Testing (News · Origin · 30 November 2025)
Pioneering gastrointestinal disease diagnostics, monitoring, and management.
Redefining gynaecological diagnostics and care.
Unlocking the potential of the human biome.
Capabilities
With offices and laboratories in London and Cambridge, we offer world-class in-house expertise that allows us to conceive, innovate, test, develop, and deliver ground-breaking technologies at speed.
We combine cross-company talent and technology sharing with the infrastructure of a much larger organisation, giving TOGL companies and select collaborators priority access to advanced platforms, processes, and departments. This model enables fast, cost-efficient, and fully controlled development of products that address urgent, unmet global healthcare needs.
Collaboration at our core
By working with others, we unlock opportunities to deliver more impactful solutions, faster.
Each of our companies pursues its own priorities, yet we actively seek new partnerships, academic or commercial, that enhance our capabilities, biobanks, data repositories, and intellectual property.
